StockNews.com Initiates Coverage on Cyclacel Pharmaceuticals (NASDAQ:CYCC)

Analysts at StockNews.com began coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC) in a report released on Monday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Cyclacel Pharmaceuticals Stock Performance

CYCC opened at $0.27 on Monday. The firm’s fifty day moving average is $0.33 and its two-hundred day moving average is $0.50. The firm has a market cap of $1.69 million, a PE ratio of -0.03 and a beta of 0.28. Cyclacel Pharmaceuticals has a twelve month low of $0.26 and a twelve month high of $4.00.

Insiders Place Their Bets

In related news, CEO David E. Lazar sold 194,628,820 shares of the business’s stock in a transaction that occurred on Wednesday, February 26th. The stock was sold at an average price of $0.03, for a total value of $5,838,864.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 23.97% of the company’s stock.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.